-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 6, at the 5th CIIE, Lilly reached a cooperation intention with Ader Biologics and Ranshi Medical to jointly promote the development of Lilly's world's first highly selective RET inhibitor, septitinib, for companion diagnostics in China, so as to benefit more RET-driven cancer patients
in China.
Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University said, "The Healthy China Action 2019-2030 clearly requires that the five-year survival rate of tumors be increased by 15%, and precision diagnosis and treatment is of great significance
to improve the five-year survival rate of cancer.
Taking the field of lung cancer as an example, in recent years, lung cancer patients who target 'rare target mutations' are no longer without drugs
.
Through accurate diagnosis, the appropriate treatment method can be screened for these patients, so as to maximize
the patient's benefit.
We hope that more effective precision diagnosis and treatment solutions can enter the clinic as soon as possible and comprehensively improve the diagnosis and treatment level and efficacy
of lung cancer in China.
"
Lilly has continued to make efforts in the field of precision therapy in recent years, and its innovative targeted drug septinib was approved by the US FDA in May 2020, becoming the world's first highly selective RET inhibitor approved, and was officially approved for marketing in China in September 2022 for patients with RET-driven lung cancer and thyroid cancer
.
Dr.
Li Wang, Senior Vice President of Lilly Global and Head of Lilly China Drug Development and Medical Affairs Center, said: "Sepretinib, which has just been approved for marketing in China, is a breakthrough in
Lilly's exploration in the field of precision oncology therapy.
The cooperation intention of Ader Biologics and Ranshi Medical, a leading local diagnostic company in China, is a milestone step taken by Lilly in the field of precision diagnosis and treatment of tumors, which will enable cepitinib to be more effective and accurately applied in Chinese clinical trials and benefit more Chinese patients
.
It
is reported that this will be the first cooperation between Lilly and China's local diagnostic company, which will focus on the highly selective RET inhibitor ceplitinib has been approved in the field of lung cancer and thyroid cancer in
China.
The two companies will jointly develop and commercialize ceplinib companion diagnostics in China for the detection of RET gene variants
in lung and thyroid cancer patients.
Limou Zheng, founder and chairman of AdMed Biologics, said, "Since 2019, Ed and Eli Lilly have begun to carry out global companion diagnosis cooperation
in the field of lung cancer.
This cooperation is an important testimony to
the deepening of the partnership between the two parties.
Han Yusheng, founder and CEO of Ranshi Medical, said, "Ranshi Medical focuses on the whole process of tumor precision medicine, and believes that our cooperation will create a standardized and high-standard model for the joint development of precision diagnosis and new anti-tumor drugs, and help the rapid development
of precision diagnosis and treatment of cancer in China.
"
Mr.
Ji Liwen, President and General Manager of Lilly China, said, "We are accelerating the introduction of more innovative oncology drugs into China, and it is a very good testimony
that cepitinib was the first to land in Boao Lecheng, Hainan before it was officially approved in China.
" Lilly has been deeply engaged in the field of cancer treatment in China for many years, and has been continuously bringing high-quality, affordable and innovative drugs
to Chinese cancer patients through independent research and development and local cooperation.
The successful signing of Lilly with two local diagnostic companies further demonstrates Lilly's philosophy
of 'rooted in China for the benefit of China'.
In the future, Lilly will continue to explore diversified cooperation models to accelerate the research and development of innovative drugs and actively promote the access
of innovative drugs.
”
in China.
Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University said, "The Healthy China Action 2019-2030 clearly requires that the five-year survival rate of tumors be increased by 15%, and precision diagnosis and treatment is of great significance
to improve the five-year survival rate of cancer.
Taking the field of lung cancer as an example, in recent years, lung cancer patients who target 'rare target mutations' are no longer without drugs
.
Through accurate diagnosis, the appropriate treatment method can be screened for these patients, so as to maximize
the patient's benefit.
We hope that more effective precision diagnosis and treatment solutions can enter the clinic as soon as possible and comprehensively improve the diagnosis and treatment level and efficacy
of lung cancer in China.
"
Lilly has continued to make efforts in the field of precision therapy in recent years, and its innovative targeted drug septinib was approved by the US FDA in May 2020, becoming the world's first highly selective RET inhibitor approved, and was officially approved for marketing in China in September 2022 for patients with RET-driven lung cancer and thyroid cancer
.
Dr.
Li Wang, Senior Vice President of Lilly Global and Head of Lilly China Drug Development and Medical Affairs Center, said: "Sepretinib, which has just been approved for marketing in China, is a breakthrough in
Lilly's exploration in the field of precision oncology therapy.
The cooperation intention of Ader Biologics and Ranshi Medical, a leading local diagnostic company in China, is a milestone step taken by Lilly in the field of precision diagnosis and treatment of tumors, which will enable cepitinib to be more effective and accurately applied in Chinese clinical trials and benefit more Chinese patients
.
It
is reported that this will be the first cooperation between Lilly and China's local diagnostic company, which will focus on the highly selective RET inhibitor ceplitinib has been approved in the field of lung cancer and thyroid cancer in
China.
The two companies will jointly develop and commercialize ceplinib companion diagnostics in China for the detection of RET gene variants
in lung and thyroid cancer patients.
Event site
Limou Zheng, founder and chairman of AdMed Biologics, said, "Since 2019, Ed and Eli Lilly have begun to carry out global companion diagnosis cooperation
in the field of lung cancer.
This cooperation is an important testimony to
the deepening of the partnership between the two parties.
Han Yusheng, founder and CEO of Ranshi Medical, said, "Ranshi Medical focuses on the whole process of tumor precision medicine, and believes that our cooperation will create a standardized and high-standard model for the joint development of precision diagnosis and new anti-tumor drugs, and help the rapid development
of precision diagnosis and treatment of cancer in China.
"
Mr.
Ji Liwen, President and General Manager of Lilly China, said, "We are accelerating the introduction of more innovative oncology drugs into China, and it is a very good testimony
that cepitinib was the first to land in Boao Lecheng, Hainan before it was officially approved in China.
" Lilly has been deeply engaged in the field of cancer treatment in China for many years, and has been continuously bringing high-quality, affordable and innovative drugs
to Chinese cancer patients through independent research and development and local cooperation.
The successful signing of Lilly with two local diagnostic companies further demonstrates Lilly's philosophy
of 'rooted in China for the benefit of China'.
In the future, Lilly will continue to explore diversified cooperation models to accelerate the research and development of innovative drugs and actively promote the access
of innovative drugs.
”
(Operation: Zhou Xinyu)
